TXNIP and colitis: Treatment with VI-16, a synthetic flavonoid that tethers NLRP3 and abrogates its binding to Thioredoxin interacting protein (TXNIP), results in a complete NLRP3 inflammasome inhibition, ameliorating colitis [83]; Compound 6, a novel tetrahydroquinoline which complex with the NACHT domain of NLRP3, inhibits NLRP3 inflammasome and attenuates colitis in in vivo mouse model [84].